Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02410694
• Other study ID #: AGMT_MM-1
• Status: Completed
• Phase: Phase 2
• Start date: April 2015
• Est. completion date: May 2, 2019

Study information

• Verified date: December 2019
• Source: Arbeitsgemeinschaft medikamentoese Tumortherapie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Overview of Study Design:

This is an open phase II, single-arm, multi-center study to evaluate progression free survival in patients receiving ixazomib in combination with thalidomide and dexamethasone (ITD) followed by an ixazomib maintenance phase of a maximum period of 12 months.

The patient population will consist of adult male and female patients with multiple myeloma (MM) with relapsed and/or refractory disease after at least one prior treatment line.

In case of enrollment patients will receive ixazomib 4.0mg at days 1, 8, 15, thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), and dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle. The proposed number of cycles is 8. Treatment will be discontinued in case of progressive disease or in case of no response after 4 cycles (≤ SD after 4 cycles). After discontinuation of therapy an end of treatment visit (EOT) will be performed within 14 days after the last dose of the last combination treatment cycle.

After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months. Patients who completed less than 8 cycles of ITD treatment do not qualify for maintenance phase.

Follow-up visits will be performed in 3-monthly intervals until the last patient on ixazomib maintenance therapy has concluded or discontinued the maintenance phase.

A safety analysis will be conducted after enrollment of the first 6 patients and completion of at least two cycles in every patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: May 2, 2019
• Est. primary completion date: March 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female patients 18 yrs or older.

2. Voluntary written consent

3. Patients in need of therapy with a diagnosis of relapsed or refractory multiple myeloma who had at least one prior treatment line

4. Patients must have measurable disease defined by at least 1 of the following criteria:

• Serum M-protein = 10g/l

• Urine M-protein = 200mg/24h

• Serum free light chain assay: involved serum light chain = 10mg/dl provided that free light chain ration is abnormal

5. Life expectancy > 3 months

6. ECOG (Eastern Cooperative Oncology Group) = 2

7. • ANC = 1.000/mm3 and platelet count = 50.000/mm3

• Total bilirubin = 2 x ULN

• ALT and AST = 3 x ULN

• GFR = 15ml/min as calculated by cockroft-Gault equation

8. Female patients who:

• Are older than 50 years and postmenopausal for at least 1 year before the screening visit, OR

• Are surgically sterile, OR

• If they are of childbearing potential, agree to practice 2 effective methods of contraception at the same time, from 4 weeks before starting study therapy through 90 days after the last dose of study drug, OR

• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

• Are informed and understand the possible consequences of the teratogenic potential of thalidomide

• Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:

• Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR

• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

• Are informed and understand the possible consequences of the teratogenic potential of thalidomide

9. Disease free of prior malignancies for = 2 years with exception of curatively treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast if they have undergone complete resection.

Exclusion Criteria:

1. lactating females or have a positive serum pregnancy test

2. Failure to have fully recovered (i.e., = Grade 1 toxicity) from the reversible effects of prior chemotherapy

3. Previous treatment with ixazomib

4. Previous treatment with bortezomib or thalidomide within the last 3 months prior to baseline visit

5. Primary refractory to, or relapsing during, or within = 6 weeks after end of treatment with a proteasome inhibitor and/or thalidomide

6. Previous anti-cancer treatment within the last 21 days prior to baseline visit (cycle 1 / day 1), except corticosteroid therapy (40 - 160mg dexamethasone or corticosteroid dose equivalent per month)

7. Major surgery within 14 days before enrollment

8. Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib.

9. Central nervous system involvement

10. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment

11. Evidence of current uncontrolled cardiovascular conditions

12. Systemic treatment, within 14 days before the first dose of ixazomib, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort

13. Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive

14. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol

15. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

16. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

17. Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast with are not excluded if they have undergone complete resection

18. Patient has = Grade 3 peripheral neuropathy or Grade 2 with pain on clinical examination during the screening period

19. Participation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Ixazomib

• Thalidomide

• Dexamethasone

Locations

Country	Name	City	State
Austria	LKH Feldkirch, Interne E	Feldkirch	Vorarlberg
Austria	Medizinische Universitätsklinik Graz, Klinische Abteilung für Hämatologie	Graz	Steiermark
Austria	UK Innsbruck, Universitätsklinik für Innere Medizin, Klinische Abteilung für Hämatologie und Onkologie	Innsbruck	Tirol
Austria	A.ö. BK Kufstein, Abteilung für Innere Medizin	Kufstein	Tirol
Austria	Kepler Universitätsklinikum Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie	Linz
Austria	KH der Elisabethinen Linz, 1. Interne Abteilung	Linz	Oberösterreich
Austria	Ordensklinikum, KH der Barmherzigen Schwestern Linz, Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie	Linz	Oberösterreich
Austria	Universitätsklinik der PMU Universitätsklinik für Innere Medizin III	Salzburg
Austria	Wilhelminenspital	Vienna
Austria	Klinikum Wels-Grieskirchen, IV. Interne Abteilung	Wels	Oberösterreich
Austria	KH der Barmherzigen Brüder Wien, Innere Medizin	Wien
Austria	Med. Universität Wien, Universitätsklinik f. Innere Medizin I, Klin. Abt. f. Hämatologie u. Hämostaseologie	Wien
Czechia	Faculty Hospital Brno and Faculty of Medicine MU Brno 2nd Internal Clinic	Brno
Czechia	Fakultní nemocnice Ostrava	Ostrava-Poruba
Germany	Universitätsklinikum Leipzig - AöR Selbstständige Abteilung für Hämatologie, Internistische Onkologie und Hämostaseologie	Leipzig
Germany	Universitätsklinikum Tübingen, Innere Medizin II	Tubingen
Germany	Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II Zentrum Innere Medizin	Wurzburg

Sponsors (1)

Lead Sponsor	Collaborator
Arbeitsgemeinschaft medikamentoese Tumortherapie

Countries where clinical trial is conducted

Austria,  Czechia,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival (PFS)		start of combination therapy to progressive disease or death due to any cause whichever occurs first, up to 4.5 years
Secondary	Overall Response Rate (ORR)		best and first response since start of therapy, up to 4,5 years
Secondary	Overall Survival (OS)		start of therapy to death, up to 4,5 years
Secondary	Renal Response in a subgroup of patients with baseline GFR 15-30ml/min		start of therapy to best renal response, up to 4,5 years
Secondary	Determination of safety by reporting of adverse events	Reporting of adverse event as a measure of safety and tolerability	start of therapy to end of study therapy (appr. 2 yrs)
Secondary	Assessment of prognostic values of risk factors at diagnosis incl. clinical assessment and cytogenetic abnormalities		screening to end of study (appr. 2 yrs)
Secondary	Correlation between altered expressions of specifically selected genes and patient´s response to the treatment regimen		screening to end of study (appr. 2 yrs)